$PALI
PALISADE BIO, INC.

2022 Q4 Form 10-Q Financial Statement

#000095017022024748 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.505M $2.075M
YoY Change -53.36% -13.25%
% of Gross Profit
Research & Development $2.343M $1.928M
YoY Change 192.88% 208.97%
% of Gross Profit
Depreciation & Amortization $2.000K $0.00
YoY Change
% of Gross Profit
Operating Expenses $3.848M $4.413M
YoY Change -4.44% 46.32%
Operating Profit -$4.413M
YoY Change 46.32%
Interest Expense $20.00K $4.000K
YoY Change -99.61% -84.62%
% of Operating Profit
Other Income/Expense, Net $108.0K $422.0K
YoY Change 881.82% -96.2%
Pretax Income -$3.720M -$3.991M
YoY Change -446.69% -149.35%
Income Tax
% Of Pretax Income
Net Earnings -$3.720M -$3.991M
YoY Change -446.69% -149.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$2.06 -$0.08
COMMON SHARES
Basic Shares Outstanding 77.08M 21.88M
Diluted Shares Outstanding 48.71M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.38M $13.99M
YoY Change 17.99% -0.84%
Cash & Equivalents $12.40M $14.00M
Short-Term Investments
Other Short-Term Assets $912.0K $1.153M
YoY Change -51.46% -42.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $14.73M $15.16M
YoY Change 19.06% -5.8%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $12.00K
YoY Change 233.33% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $694.0K $746.0K
YoY Change 2569.23% 2769.23%
Total Long-Term Assets $1.030M $1.108M
YoY Change 646.38% 508.79%
TOTAL ASSETS
Total Short-Term Assets $14.73M $15.16M
Total Long-Term Assets $1.030M $1.108M
Total Assets $15.76M $16.27M
YoY Change 25.98% -0.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.759M $1.725M
YoY Change 32.96% 24.73%
Accrued Expenses $574.0K $1.242M
YoY Change 23.97% 72.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $88.00K $352.0K
YoY Change 1.15% -38.03%
Total Short-Term Liabilities $3.012M $3.513M
YoY Change 20.67% 20.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $272.0K $323.0K
YoY Change -89.74% -96.58%
Total Long-Term Liabilities $272.0K $323.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.012M $3.513M
Total Long-Term Liabilities $272.0K $323.0K
Total Liabilities $3.284M $3.836M
YoY Change -36.2% -68.95%
SHAREHOLDERS EQUITY
Retained Earnings $109.2M $105.2M
YoY Change 15.43% -209.93%
Common Stock $30.00K $771.0K
YoY Change -79.02% 493.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.48M $12.43M
YoY Change
Total Liabilities & Shareholders Equity $15.76M $16.27M
YoY Change 25.98% -0.05%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.720M -$3.991M
YoY Change -446.69% -149.35%
Depreciation, Depletion And Amortization $2.000K $0.00
YoY Change
Cash From Operating Activities -$3.306M -$3.040M
YoY Change 8.22% 10.71%
INVESTING ACTIVITIES
Capital Expenditures $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$10.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.714M 12.05M
YoY Change -409.39% 165.02%
NET CHANGE
Cash From Operating Activities -3.306M -3.040M
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 1.714M 12.05M
Net Change In Cash -1.602M 9.005M
YoY Change -55.61% 520.61%
FREE CASH FLOW
Cash From Operating Activities -$3.306M -$3.040M
Capital Expenditures $10.00K
Free Cash Flow -$3.316M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2021Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33672
dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 5200
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
704-4900
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
PALI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77080169
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13985000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
15158000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11506000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
324000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
746000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
868000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2022Q3 us-gaap Assets
Assets
16266000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7259000
CY2022Q3 us-gaap Restructuring Costs
RestructuringCosts
410000
CY2021Q3 us-gaap Restructuring Costs
RestructuringCosts
0
CY2021Q4 us-gaap Assets
Assets
12512000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1725000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1323000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1242000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
93000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
511000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
101000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2022Q3 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
352000
CY2021Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
87000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3513000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2496000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
84000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2651000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
239000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
3836000
CY2021Q4 us-gaap Liabilities
Liabilities
5147000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77080169
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77080169
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14239177
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14239177
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
771000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116839000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101862000
CY2022Q3 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-105182000
CY2021Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-94642000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12430000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16266000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12512000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1928000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
624000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4204000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1630000
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2075000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6080000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2392000
us-gaap Restructuring Costs
RestructuringCosts
410000
us-gaap Restructuring Costs
RestructuringCosts
0
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4413000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
3016000
us-gaap Operating Expenses
OperatingExpenses
11873000
us-gaap Operating Expenses
OperatingExpenses
37827000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4413000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3016000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11873000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37827000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2022Q3 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2021Q3 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
385000
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12764000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2403000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17939000
CY2022Q3 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021Q3 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
18000
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
CY2022Q3 us-gaap Interest Expense
InterestExpense
4000
CY2021Q3 us-gaap Interest Expense
InterestExpense
26000
us-gaap Interest Expense
InterestExpense
10000
us-gaap Interest Expense
InterestExpense
2393000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36000
CY2022Q3 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021Q3 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
CY2022Q3 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2021Q3 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1673000
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
3247000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
422000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11103000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1333000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10138000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-191000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.13
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48709846
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12100292
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28634209
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7902104
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48709846
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12106771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28634209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7952998
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3991000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5118000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10540000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27689000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3991000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5119000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10540000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-32808000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4211000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12430000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-9444000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
CY2021Q3 pali Conversion Of Share Liability To Common Stock
ConversionOfShareLiabilityToCommonStock
33000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3920000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
946000
pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1274000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12430000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1184000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28728000
pali Stock Acquired During Period Value
StockAcquiredDuringPeriodValue
2000
pali Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger
AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger
51000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-84000
us-gaap Share Based Compensation
ShareBasedCompensation
1208000
pali Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants
AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants
26000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
213000
pali Conversion Of Share Liability To Common Stock
ConversionOfShareLiabilityToCommonStock
33000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1208000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3920000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
0
pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
-135000
pali Noncash Lease Expense
NoncashLeaseExpense
140000
pali Noncash Lease Expense
NoncashLeaseExpense
122000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
us-gaap Accretion Expense
AccretionExpense
0
us-gaap Accretion Expense
AccretionExpense
2334000
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
3247000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2403000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17939000
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
us-gaap Share Based Compensation
ShareBasedCompensation
946000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-744000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1264000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
706000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2145000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-418000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1544000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-127000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-122000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10054000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11718000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3279000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
3333000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
148000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
524000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
949000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
19900000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14401000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5209000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
99000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
333000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13544000
pali Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
67000
pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25163000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3490000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13391000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14011000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14130000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13985000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14104000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14011000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14130000
us-gaap Interest Paid Net
InterestPaidNet
10000
us-gaap Interest Paid Net
InterestPaidNet
61000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
355000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
pali Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
683000
pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
55000
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
0
pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
459000
pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
58000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssets
784000
pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssets
772000
pali Purchase Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
10000
pali Purchase Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
0
pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
0
pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
135000
pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
0
pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
1184000
pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
0
pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
28728000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9503000
pali Assets Assumed1
AssetsAssumed1
0
pali Assets Assumed1
AssetsAssumed1
2000
pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
0
pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
41000
pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
0
pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
51000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
105200000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14000000.0
CY2022Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
81000
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to clinical trial accruals, and the valuation of derivative liabilities and stock-based compensation instruments. Although these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q3 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
12100292
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
28634209
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
7902104
CY2022Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2021Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
6479
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
50894
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span></p>
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2022Q3 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
257000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
2969000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3991000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5118000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10540000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27689000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48709846
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12100292
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28634209
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7902104
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
8087000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Net Income Loss
NetIncomeLoss
-27689000
CY2022Q3 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021Q3 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
-5119000
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
2968000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3991000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5119000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10540000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-32808000
CY2022Q3 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
48709846
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48709846
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12106771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28634209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7952998
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
125518367
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9290568
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11506000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
868000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2021Q4 us-gaap Assets
Assets
12512000
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
377474
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.45
CY2022Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-08-26
CY2022Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
111250
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
110000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
807000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
540000
CY2022Q3 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
20000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
150000
CY2022Q3 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
205000
CY2021Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
215000
CY2022Q3 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
54000
CY2021Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
78000
CY2022Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
81000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
28000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011000
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7181741
CY2021Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
7181741
CY2022Q3 pali Accrued Accounts Payable
AccruedAccountsPayable
482000
CY2021Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
195000
CY2022Q3 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
257000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2022Q3 pali Accrued Director Stipends
AccruedDirectorStipends
111000
CY2021Q4 pali Accrued Director Stipends
AccruedDirectorStipends
110000
CY2022Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
392000
CY2021Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1242000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
734000
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
868000
CY2022Q3 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
746000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
868000
CY2021Q3 us-gaap Warrants And Rights Outstanding Measurement Input
WarrantsAndRightsOutstandingMeasurementInput
3900000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
122924912000
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.96
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y5M12D
pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
119827491
pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
0.28
pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P3Y14D
pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
3994302
pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
3.88
pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P4Y1M9D
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
90018
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
81.37
CY2022Q3 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
122924912
pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.44
pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P3Y14D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.81
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.72
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0230
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0088
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7366
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7605
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1956855
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
792600
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.81
pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y6M
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
162479
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2586976
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M29D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2586976
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M29D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1392169
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M20D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
950000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
103000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
946000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1208000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000.0
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2022Q3 pali Milestone Payments
MilestonePayments
0
pali Milestone Payments
MilestonePayments
0
CY2021Q3 pali Milestone Payments
MilestonePayments
0
pali Milestone Payments
MilestonePayments
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
43000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
133000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
137000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
82000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
395000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
55000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
340000

Files In Submission

Name View Source Status
0000950170-22-024748-index-headers.html Edgar Link pending
0000950170-22-024748-index.html Edgar Link pending
0000950170-22-024748.txt Edgar Link pending
0000950170-22-024748-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img60049379_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20220930.htm Edgar Link pending
pali-20220930.xsd Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
pali-ex4_33.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
pali-20220930_cal.xml Edgar Link unprocessable
pali-20220930_def.xml Edgar Link unprocessable
pali-20220930_lab.xml Edgar Link unprocessable
pali-20220930_pre.xml Edgar Link unprocessable
pali-20220930_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable